BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 8497368)

  • 1. Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer.
    Plante M; Wong GY; Nisselbaum JS; Almadrones L; Hoskins WJ; Rubin SC
    Obstet Gynecol; 1993 Jun; 81(6):989-92. PubMed ID: 8497368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saliva and serum CA 125 assays for detecting malignant ovarian tumors.
    Chen DX; Schwartz PE; Li FQ
    Obstet Gynecol; 1990 Apr; 75(4):701-4. PubMed ID: 2179784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Primary research on saliva and serum CA125 assays for detecting malignant ovarian tumors].
    Chen DX; Li FQ
    Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):84-5, 123-4. PubMed ID: 2364796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer.
    Zurawski VR; Broderick SF; Pickens P; Knapp RC; Bast RC
    Obstet Gynecol; 1987 Apr; 69(4):606-11. PubMed ID: 2434895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyst fluid CA 125 levels in ovarian epithelial neoplasms.
    Menczer J; Ben-Baruch G; Moran O; Lipitz S
    Obstet Gynecol; 1993 Jan; 81(1):25-8. PubMed ID: 8416456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
    Einhorn N; Bast RC; Knapp RC; Tjernberg B; Zurawski VR
    Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The value of CA 125 determination in the serum of patients with ovarian cancer].
    Bartel U; Johannsen B; Elling D
    Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of CA-125 tumor marker determination in patients with ovarian carcinoma].
    Miladinović D; Paunović R; Paunković N
    Jugosl Ginekol Perinatol; 1989; 29(3-4):83-5. PubMed ID: 2601371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
    Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
    Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative serum tumor-associated antigen levels in women with pelvic masses.
    Soper JT; Hunter VJ; Daly L; Tanner M; Creasman WT; Bast RC
    Obstet Gynecol; 1990 Feb; 75(2):249-54. PubMed ID: 2300353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer.
    Einhorn N; Sjövall K; Knapp RC; Hall P; Scully RE; Bast RC; Zurawski VR
    Obstet Gynecol; 1992 Jul; 80(1):14-8. PubMed ID: 1603484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the CA 125 assay in the management of ovarian cancer.
    Niloff JM
    Oncology (Williston Park); 1988 Aug; 2(8):67-76. PubMed ID: 3275060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
    Jacobs IJ; Oram DH; Bast RC
    Obstet Gynecol; 1992 Sep; 80(3 Pt 1):396-9. PubMed ID: 1495694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA-125 in peritoneal fluid from patients with nonmalignant gynecologic disorders.
    Ismail MA; Rotmensch J; Mercer LJ; Block BS; Salti GI; Holt JA
    J Reprod Med; 1994 Jul; 39(7):510-2. PubMed ID: 7966039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.
    Chen DX; Schwartz PE; Li XG; Yang Z
    Obstet Gynecol; 1988 Jul; 72(1):23-7. PubMed ID: 3164105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experiences with the cancer marker CA 125 in gynecologic diseases].
    Pilgrim G; von Broen B; Johannsmeyer KD
    Z Gesamte Inn Med; 1989 Apr; 44(8):251-4. PubMed ID: 2741520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of monoclonal antibody OC 125 in gynecological oncology].
    Wu AR; Wang EY; Wang XX; Jia XH; Li L
    Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients.
    Hefler L; Tempfer C; Heinze G; Mayerhofer K; Breitenecker G; Leodolter S; Reinthaller A; Kainz C
    Br J Cancer; 1999 Nov; 81(5):855-9. PubMed ID: 10555758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer.
    Crombach G; Zippel HH; Würz H
    Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.